LITESPARK-005 evaluated belzutifan against everolimus in advanced renal cell carcinoma (RCC), demonstrating significant progression-free survival improvement but failing to meet the overall survival (OS) co-primary endpoint. Despite FDA approval, the trial highlights key obstacles in drug development in RCC, given the absence of OS improvement, lack of biomarker studies, high financial toxicity, and limited accessibility outside the United States.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.11.016 | DOI Listing |
Publication Analysis
Top Keywords
renal cell
8
cell carcinoma
8
belzutifan renal
4
carcinoma balancing
4
balancing regulatory
4
regulatory approval
4
approval societal
4
societal patient
4
patient impact
4
impact litespark-005
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!